influenzae b infections.
Susceptibility to systemic H. influenzae b infections in children is strongly associated with absence of serum antibodies directed against the type b capsular polysaccharide, polyribosylribitol phosphate (PRP) (12) . Similarly, immunization of children more than 2 years old with purified type b capsular PRP vaccine, which has recently been marketed in the United States for children 24 months of age, confers protection against invasive disease (13) . In contrast, the relationship between anticapsular antibodies and protection against invasive H. influenza b disease in adults is less well understood. In this study, to identify groups of adults that may benefit from immunization with H. influenza b vaccine, we attempted to identify associations between certain underlying illnesses or health-related variables and low levels of anticapsular antibodies. Sera from 400 patients hospitalized at an adult general hospital were tested for anti-PRP antibodies, and the results were correlated with 26 health-related variables, including 3 personal characteristics, 10 Anti-PRP antibody assay. Serum immunoglobulin G antibodies to H. influenza b capsular PRP were quantitated by using an enzyme-linked immunosorbent assay. Capsular PRP was isolated and purified from the supernatant of a broth culture of H. influenzae b by using the method of Kuo et al. (10) , and the amount of PRP in the purified preparation was quantitated by latex agglutination, with PRP purified by Lederle Laboratories (kindly provided by Christine Williams) as a reference standard. The PRP was conjugated to tyramine (PRP-tyramine) by using cyanogen bromide as described by Anthony et al. (1) to enhance uniform binding to polystyrene microtiter plates. The PRP-tyramine was diluted in carbonate-coating buffer (21) to a concentration of 5.72 1tg of PRP per ml, and U-bottom, rigid, polystyrene microtiter wells (Dynatech Laboratories, Inc., Alexandria, Va.) were coated with 100 ,ul (0.57 ,ug) of PRP-tyramine for 18 h at 4°C. Results of preliminary experiments confirmed that the microtiter wells were saturated with this amount of antigen.
After being coated, the wells were washed for 1 h with 100 ,uI of phosphate-buffered saline (pH 7.4) containing 0.3% Tween 20 (PBS-T). All washes and incubations were performed at room temperature on a rotating platform at 50 rpm. A total of 100 ,ul of each test serum, diluted 1:50 in PBS-T, was added to the wells, incubated for 1 h, and then washed twice with PBS-T for 5 min. Then, 100 ,ul of affinity-purified goat anti-human immunoglobulin G, heavy and light chain specific, conjugated with horseradish peroxidase (Cappel Laboratories, Malvern, Pa.) was added. After 1 h of incubation, the wells were again washed with PBS-T twice for 5 The correlation between the lower anti-PRP value and increasing age was 0.0934 (P = 0.068). Table 2 presents the mean anti-PRP levels by sex and race. By two-way contingency table analysis, the P value for the association between anti-PRP level and race (Caucasian versus non-Caucasian) was 0.051. Sex was not associated with anti-PRP level. Table 3 presents the mean anti-PRP levels of patients for various illness variables and strata; we identifed no significant associations among anti-PRP levels and any of these variables. Table 4 presents mean anti-PRP levels in patients with four drug use variables. Steroid therapy was associated with low anti-PRP levels by analysis of variance (P = 0.041) and by two-way contingency table analysis (Fisher exact test; P = 0.057). Additional analysis of variance, using the collapsed variables, drug usage, and no drug usage, confirmed a significant association between low anti-PRP levels and steroid usage (P = 0.012). We also demonstrated by analysis of variance a significant association between low anti-PRP levels and use of immunosuppressive therapy (P = 0.045).
Least squares regression modeling with dummy variables against the transformed anti-PRP value resulted in marginally significant coefficients for steroid therapy (P = 0.041, R2 = 0.021), age (P = 0.074, R2 = 0.008), and steroid therapy (1) 2 (1) 8 (2) S (1) 5 (1) 4 (1) 246 (64) 57 (15) 13 (3) 52 (13) 20 (5) 351 (91) 19 (5) 6 (2) 11 (3) 1 (0) 375 (97) 6 (2) 1 (0) 6 (2) 368 (96) 4 (1) 1 (0) 6 (2) 3 (1) 3 (1) 374 (96) 3 (1) 9 (2) 2 (1) 40. and age together (P = 0.021, R2 = 0.035). All-possiblesubsets analysis generated a best model of age, steroid therapy, and rheumatologic illness against the transformed anti-PRP value (P = 0.004), but the R2 value remained low, (0.038).
The assay variability (expressed as a coefficient of variation) of anti-PRP values was 4.2% for well-to-well differences, 4.1 to 32.9% for plate-to-plate differences, and 15.4% for day-to-day differences. (4, 20) .
We attempted to identify certain underlying illnesses or clinical parameters in adult individuals that may be predictive of low levels of serum antibody directed against H. influenzae type b PRP. The only factor that was consistently identified as having an association with low serum anti-PRP levels was steroid use. However, we did not identify a relationship between the steroid dose and the level of anti-PRP antibodies. Interestingly, among patients with rheumatologic disease, those that required cytotoxic agents or remititive agents had low levels of anti-PRP antibody, whereas those that were steroid controlled did not; however, the numbers of patients in these groups are sniall.
Although the correlation between age and concentration of anti-PRP antibody was not statistically significant at the 5% level, a possible trend toward decreased anti-PRP antibody with increased age was observed. However, in spite of these associations, none of the variables tested were predictive of low levels of antibodies directed against anti-PRP antibody. By multivariate analysis, only 4% of the variability of the antibody levels was accounted for by the best model, indicating that many factors that we did not identify influence anti-PRP levels.
A possible explanation for our failure to identify more clinical parameters that were associated with anti-PRP levels may be that, although the total number of patients studied was large, the numbers of patients with each category and stratum tended to be small and the levels of serum anti-PRP antibody were widely variable among the patients tested. Because of this high variability, a higher number of patients within each disease category would be required to identify a significant association. In addition, identification of associations by using contingency Previously published studies of anti-PRP levels and of responses to vaccination with the H. influenza b capsular polysaccharide have used radioahtigen-binding assays for antibody determination (7, 12) . By this technique, the amoudit of antibody required to assure protection against disease in children following vaccination has been estimated to be greater than 1 ,ug/ml (9) . More Identification of a group of patients with an underlying illness predictive of low levels of anti-PRP antibody may provide a target group of adults to receive the H. influenza type b vaccine. However, other factors in the immune response to PRP that are not addressed in this study, such as booster response to antigenic stimulation, may be important in protection against H. influenza b infection (7). In addition, the only group that we identified as being associated with lower anti-PRP levels were those patients using steroids or immunosuppressive agents, who may be unable to generate an adequate immune response to vaccination (15, 17, 18) .
Furthermore, the efficacy of another polysaccharide vaccine, the pneumococcal polysaccharide vaccine, in adults remains controversial (2, 19 
